Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present MyoKardia, Inc. (NASDAQ: MYOK).

Full DD Report for MYOK

You must become a subscriber to view this report.


Recent News from (NASDAQ: MYOK)

MyoKardia beats by $0.11, beats on revenue
MyoKardia (NASDAQ: MYOK ): Q3 GAAP EPS of -$0.39 beats by $0.11 . More news on: MyoKardia, Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: November, 07 2018 17:46
MyoKardia Reports Third Quarter 2018 Financial Results
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today reported financial results for the quarter ended September 30, 2018.&#x...
Source: GlobeNewswire
Date: November, 07 2018 16:30
MyoKardia to Present at the Credit Suisse 27th Annual Healthcare Conference
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced today announced that Jake Bauer, Chief Business Officer,...
Source: GlobeNewswire
Date: November, 07 2018 08:01
MyoKardia to Present Clinical Evidence of Mavacamten's Effect on Diastolic Function at 2018 American Heart Association Scientific Sessions
Diastolic Relaxation Typically Impaired in HCM Patients; Data Indicate Mavacamten May Improve Ability of the Left Ventricle to Relax and Fill Additional Clinical Evidence of Mavacamten’s Effect on Diastolic Function Expected in 2H 2019 from MyoKardia’s MAVERICK-HCM Phase...
Source: GlobeNewswire
Date: November, 05 2018 08:00
MyoKardia Announces Twelve Abstracts Accepted for Presentation During the 2018 American Heart Association Scientific Sessions
Presentations Include Data from Ongoing Clinical Trials and Preclinical Studies of Mavacamten and HCM Population Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe) MyoKardia Management to Host a Conference Call on November 12 at 8:00 a.m. ET to Review Data SOUTH SAN...
Source: GlobeNewswire
Date: November, 05 2018 08:00
MyoKardia sets milestones during R&D day
At its R&D Day today, MyoKardia ( MYOK +1.2% ) will present the following future milestones: More news on: MyoKardia, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: October, 30 2018 09:59
MyoKardia Shares Data from Ongoing Clinical Programs and Details Three New Research Programs at 2018 R&D Day
Interim PIONEER-OLE Data for Mavacamten Demonstrate Reductions in LVOT Obstruction; Ejection Fraction Maintained above Normal Range First-in-Human Data for MYK-491 in Healthy Volunteers Presented; Phase 2a Multiple-ascending Dose Trial Initiated Introduced MYK-224, ACT-1 and LUS-...
Source: GlobeNewswire
Date: October, 30 2018 07:30
MyoKardia Announces Initiative to Create Hypertrophic Cardiomyopathy Patient Community in Collaboration with 23andMe
First-of-its-kind Digital Platform for HCM Patients Intended to Provide a Powerful Patient Resource to Improve Disease Understanding and Deepen Patient Engagement and Advocacy SOUTH SAN FRANCISCO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc., (Nasdaq: MYOK), a clinical sta...
Source: GlobeNewswire
Date: October, 25 2018 00:00
MyoKardia (MYOK) Presents At 2018 Wells Fargo Securities Healthcare Conference - Slideshow
The following slide deck was published by MyoKardia in conjunction with this Read more ...
Source: SeekingAlpha
Date: September, 06 2018 14:58
MyoKardia to Present at Two Upcoming Investor Conferences in September
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of cardiovascular diseases, today announced that senior company management will be participating in the fo...
Source: GlobeNewswire
Date: August, 29 2018 16:01

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-1460.7561.7062.3060.65198,419
2017-08-2243.7543.8045.0542.5824541,191
2017-08-2141.2043.2543.5040.40749,650
2017-08-1843.3040.37544.2839.70942,622
2017-08-1742.0043.5044.2042.00862,496

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1412,73818,13270.2515Short
2018-12-1317,61826,96665.3341Short
2018-12-1225,21435,45671.1135Short
2018-12-11112,062166,15667.4438Short
2018-12-1018,35090,44620.2883Cover

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on MYOK.


About MyoKardia, Inc. (NASDAQ: MYOK)

Logo for MyoKardia, Inc. (NASDAQ: MYOK)

Not available

 

Contact Information

 

 

Current Share Structure

  • Market Cap: $1,818,084,384 - 05/17/2018
  • Issue and Outstanding: 35,966,061 - 05/05/2018

 


Recent Filings from (NASDAQ: MYOK)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: August, 08 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: August, 08 2018
Statement of beneficial ownership of common stock by certain persons
Filing Type: SC 13GFiling Source: edgar
Filing Date: July, 13 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: June, 15 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: May, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 23 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 21 2018
Prospectus filed under Rule 424(b)(5)
Filing Type: 424B5Filing Source: edgar
Filing Date: May, 21 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: May, 08 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 08 2018

 

 


Daily Technical Chart for (NASDAQ: MYOK)

Daily Technical Chart for (NASDAQ: MYOK)


Stay tuned for daily updates and more on (NASDAQ: MYOK)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: MYOK)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in MYOK is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of MYOK and does not buy, sell, or trade any shares of MYOK. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/